HomeComparePWCDF vs ABBV

PWCDF vs ABBV: Dividend Comparison 2026

PWCDF yields 3.78% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $32.6K in total portfolio value
10 years
PWCDF
PWCDF
● Live price
3.78%
Share price
$48.07
Annual div
$1.82
5Y div CAGR
31.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$69.8K
Annual income
$15,778.92
Full PWCDF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PWCDF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPWCDFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PWCDF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PWCDF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PWCDF
Annual income on $10K today (after 15% tax)
$320.99/yr
After 10yr DRIP, annual income (after tax)
$13,412.08/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $7,643.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PWCDF + ABBV for your $10,000?

PWCDF: 50%ABBV: 50%
100% ABBV50/50100% PWCDF
Portfolio after 10yr
$86.0K
Annual income
$20,275.34/yr
Blended yield
23.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PWCDF
No analyst data
Altman Z
0.1
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PWCDF buys
0
ABBV buys
0
No recent congressional trades found for PWCDF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPWCDFABBV
Forward yield3.78%3.06%
Annual dividend / share$1.82$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR31.3%40.6%
Portfolio after 10y$69.8K$102.3K
Annual income after 10y$15,778.92$24,771.77
Total dividends collected$43.8K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PWCDF vs ABBV ($10,000, DRIP)

YearPWCDF PortfolioPWCDF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,196$495.83$11,550$430.00$354.00ABBV
2$12,661$681.19$13,472$627.96$811.00ABBV
3$14,492$945.26$15,906$926.08$1.4KABBV
4$16,834$1,327.73$19,071$1,382.55$2.2KABBV
5$19,905$1,892.58$23,302$2,095.81$3.4KABBV
6$24,045$2,746.05$29,150$3,237.93$5.1KABBV
7$29,798$4,070.42$37,536$5,121.41$7.7KABBV
8$38,074$6,190.01$50,079$8,338.38$12.0KABBV
9$50,445$9,705.36$69,753$14,065.80$19.3KABBV
10$69,755$15,778.92$102,337$24,771.77$32.6KABBV

PWCDF vs ABBV: Complete Analysis 2026

PWCDFStock

Power Corporation of Canada operates as an international management and holding company in North America, Europe, and Asia. It operates through Lifeco, IGM Financial, and GBL segments. The company offers life, disability, critical illness, accidental death, dismemberment, health and dental protection, and creditor insurance; retirement and investment management; asset management; and reinsurance and retrocession; investment advisory, financial planning, and related services; and fund, protection, and wealth management services. It also provides employer-sponsored defined contribution plan, individual retirement account and drawdown, enrollment, communication material, investment option, and education services, as well as taxable brokerage accounts; private label recordkeeping and administrative services; payout annuities, equity release mortgages, life bonds, mortgage, securities, pension, private equity, debt and thematic fund, and financial services; and investment products, such as equity, fixed income, absolute return and alternative strategies, exchange traded funds, trust funds, and model-based separately managed accounts and portfolios. In addition, the company holds interests in various businesses, such as mineral-based specialty solutions; testing, inspection, and certification; cement, aggregates, and concrete; wines and spirits; sportswear and sports equipment design and distribution; materials technology and recycling of precious metals; disposable hygiene products; Atlantic salmon; customer experience and business process outsourcing; regional leisure parks; mobile game development and publishing; and bicycle manufacturing. Further, it generates renewable energy through solar and wind facilities; and designs, develops, and manufactures specification-grade LED solutions and zero-emission vehicles. The company was incorporated in 1925 and is based in Montréal, Canada. Power Corporation of Canada operates as a subsidiary of Pansolo Holding Inc.

Full PWCDF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PWCDF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PWCDF vs SCHDPWCDF vs JEPIPWCDF vs OPWCDF vs KOPWCDF vs MAINPWCDF vs JNJPWCDF vs MRKPWCDF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.